MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

18.19 0.33

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.93

Max

18.27

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

78.892

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+12.21% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.38%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

45M

390M

Iepriekšējā atvēršanas cena

17.86

Iepriekšējā slēgšanas cena

18.19

Ziņu noskaņojums

By Acuity

50%

50%

151 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 30. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

WiseTech to Sell Expedient to Appease Competition Regulator

2025. g. 30. dec. 17:12 UTC

Galvenie tirgus virzītāji

CapsoVision Shares Rise on FDA Application for AI Tool in Swallowable Camera

2025. g. 30. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 30. dec. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Penguin Solutions: Smart Modular to Sell Zilia Stake for $46M

2025. g. 30. dec. 21:08 UTC

Tirgus saruna

U.S. Natural Gas Futures Take Another Wild Ride -- Market Talk

2025. g. 30. dec. 20:41 UTC

Tirgus saruna

Oil Futures Settle Lower in Sluggish Trade -- Market Talk

2025. g. 30. dec. 20:37 UTC

Peļņas

The 5 Best Names to Play AI in 2026, According to Wall Street's Loudest Tech Bull -- Barrons.com

2025. g. 30. dec. 19:29 UTC

Tirgus saruna

Corn Extends Pullback in Light Trade -- Market Talk

2025. g. 30. dec. 18:29 UTC

Tirgus saruna

U.S. Oil Rig Count Rises By Three to 412 -- Market Talk

2025. g. 30. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 30. dec. 16:20 UTC

Peļņas

Boeing Stock Is on a Roll. Why It Could Gain 25% in the Next Year. -- Barrons.com

2025. g. 30. dec. 16:18 UTC

Iegādes, apvienošanās, pārņemšana

Meta Buys AI Startup Manus, Adding Millions of Paying Users -- 2nd Update

2025. g. 30. dec. 16:10 UTC

Tirgus saruna

Eurozone Government Bond Yields Rise, Euro Falls Ahead of Fed Minutes -- Market Talk

2025. g. 30. dec. 15:24 UTC

Tirgus saruna

Australian Dollar Could Rise Versus Sterling -- Market Talk

2025. g. 30. dec. 15:10 UTC

Iegādes, apvienošanās, pārņemšana

Meta Stock Rises After Buying Manus. What the China-Founded AI Start-Up Brings. -- Barrons.com

2025. g. 30. dec. 14:24 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: The Three Publications Are Challenges, Sciences & Avenir, and La Recherche

2025. g. 30. dec. 14:22 UTC

Iegādes, apvienošanās, pārņemšana

LVMH : Szafran Will Serve as Publishing Director For all Three Publications

2025. g. 30. dec. 14:20 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: As Part of the Deal, Maurice Szafran Has Been Named President of Les Editions Croque Futur

2025. g. 30. dec. 14:17 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: The Deal Also Reflects LVMH's Commitment to Support High-Quality Information and Scientific Culture

2025. g. 30. dec. 14:16 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: The Deal Aims to Accelerate the Development and Distribution of the Publications Mainly in Digital Format

2025. g. 30. dec. 14:14 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: The Move Includes Three Publications Into UFIPAR Investment Company

2025. g. 30. dec. 14:12 UTC

Iegādes, apvienošanās, pārņemšana

LVMH: Les Editions Croque Futur Is a French Publishing House

2025. g. 30. dec. 14:10 UTC

Iegādes, apvienošanās, pārņemšana

LVMH Acquires Les Editions Croque Futur

2025. g. 30. dec. 13:49 UTC

Iegādes, apvienošanās, pārņemšana

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

2025. g. 30. dec. 13:36 UTC

Tirgus saruna

U.S. Natural Gas Continues Weather-Driven Rally -- Market Talk

2025. g. 30. dec. 13:30 UTC

Tirgus saruna

Crude Futures Gain in Light Holiday Trade -- Market Talk

2025. g. 30. dec. 12:55 UTC

Tirgus saruna

Triple Flag Precious Metals Offers Opportunity While Mitigating Risk -- Market Talk

2025. g. 30. dec. 11:55 UTC

Tirgus saruna
Peļņas

Investors Await Tesco's Profit Outlook Following U.K. Budget Reforms -- Market Talk

2025. g. 30. dec. 11:47 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Meta's Manus Deal Is a Taster of AI Trends for 2026. Watch This Risk. -- Barrons.com

2025. g. 30. dec. 11:35 UTC

Iegādes, apvienošanās, pārņemšana

Meta Buys Manus. What the China-Founded AI Start-Up Brings for Zuckerberg. -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

12.21% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  12.21%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

151 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat